Find a Clinical Trial

Showing 191 - 200 of 238 Trials

  • A Study of PARG Inhibitor IDE161 in Participants with Advanced Solid Tumors

    Principal Investigator:

    Benjamin Herzberg, MD

    Contact Number:

    212-342-5162

    NCT Number:

    NCT05787587

    Population:

    Adult

    Phase:

    I
    The purpose of this study is to find out if the experimental study drug called IDE161 used alone is safe and helpful in solid tumors known to be caused by an error in genes that repair DNA. Cells have different ways to repair damaged DNA. Experimental means that the study drug has not been approved by any regulatory authorities, including the U.S. Food and Drug Administration (FDA) .IDE161 may block the ability of a protein called Poly(ADP-ribose) glycohydrolase (PARG) from properly functioning. PARG is an important protein in a different DNA repair pathway called Base Excision Repair (BER)...

  • A Phase 1/1b Study of ASP2138 as Monotherapy and in Combination with Pembrolizumab and mFOLFOX6 or Ramucirumab and Paclitaxel in Participants with Metastatic or Locally Advanced Unresectable Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma and in

    Principal Investigator:

    Ryan H. Moy, MD, PhD

    Contact Number:

    212-342-5162

    NCT Number:

    NCT05365581

    Population:

    Adult

    Phase:

    I
    The goal of this study is to see if a study drug called ASP2138 is safe and effective for people diagnosed with tumors known to have Claudin (CLDN) 18.2 expression. CLDN is a group of proteins seen in gastric-specific, gastroesophageal junction (GEJ) or pancreatic cancer types. The study will also see how ASP2138 is processed in the blood. Each participant will complete a number of procedures and blood collections in order to find the best dose of ASP2138. When this dosage is identified, it will be used to evaluate if ASP2138 causes tumors to shrink. ASP2138 will be assessed continuously...

  • A phase 1 study of JNJ-86974680, an A2a receptor antagonist, administered asmonotherapy and in combination with cetrelimab and radiotherapy for advanced nonsmallcell lung cancer

    Principal Investigator:

    Brian Henick, MD

    Contact Number:

    212-342-5162

    NCT Number:

    NCT06116786

    Population:

    Adult

    Phase:

    I
    The purpose of this study is to find out if JNJ-86974680 taken by itself or together with Cetrelimab and radiotherapy can cause side effects which are unexpected or unwanted reactions. This is the first time that JNJ-86974680 is being used in people. Radiotherapy is also part of the study treatment and not part of your standard of care. JNJ-86974680 and Cetrelimab are experimental drugs and not approved by the Food and Drug Administration (FDA). JJNJ-86974680 is a small molecule that may block adenosine function. Adenosine is a chemical in the body that can reduce the ability of your immune...

  • A Phase 1 Open-Label, Multi-Center, Safety and Efficacy Study of PRT3789 as Monotherapy and in Combination with Docetaxel in Participants with Advanced or Metastatic Solid Tumors with a SMARCA4 Mutation

    Principal Investigator:

    Benjamin Herzberg, MD

    Contact Number:

    212-342-5162

    NCT Number:

    NCT05639751

    Population:

    Adult

    Phase:

    I
    The purpose of this research study is to test the safety of an investigational drug, PRT3789, at different dose levels to find out what effects, good and/or bad, PRT3789 has on Advanced or Metastatic Solid Tumors with a SMARCA4 Mutation. Mutations are changes or alterations in the DNA (genetic material) of your cells. A SMARCA4 mutation has been linked to certain cancers. Investigational means that the study drug is currently being tested and has not been approved for use by any health authority such as the United States (US) Food and Drug Administration (FDA) or any other health or...

  • A Phase 1 Study of JNJ-87189401 (PSMA-CD28 Bispecific Antibody) Combined with JNJ 78278343 (KLK2-CD3 Bispecific Antibody) for Advanced Prostate Cancer

    Principal Investigator:

    Mark N. Stein, MD

    Contact Number:

    212-342-5162

    NCT Number:

    NCT06095089

    Population:

    Adult

    Phase:

    I
    The purpose of this study is to find out the side effects of JNJ-87189401 given in combination with JNJ-78278343 to patients with metastatic castration-resistant prostate cancer, and to find which doses of the two study drugs when given in combination cause the least side effects. The study will also look at how long JNJ-87189401 and JNJ-78278343 stay in the body, how they act on the body, and how the body responds to them. JNJ-87189401 and JNJ-78278343 have not been approved by the Food and Drug Administration (FDA). This is the first time that JNJ-87189401 will be used in people. JNJ-...

  • An Open-Label Phase 1b Study Evaluating the Safety and Efficacy of ABBV-383 in AL Amyloidosis

    Principal Investigator:

    Rajshekar Chakraborty, MD

    Contact Number:

    212-342-5162

    NCT Number:

    NCT06158854

    Population:

    Adult

    Phase:

    I
    The purpose of this study is to see how safe and effective is the study drug, ABBV-383. ABBV-383 works by binding to a specific protein called B-cell maturation antigen, which is found on the surface of cells affected by amyloidosis. By engaging T-cells, a type of white blood cell, ABBV-383 helps activate the immune response to target and remove the abnormal proteins that cause amyloidosis. The study drug ABBV-383, is not approved by the U.S Food and Drug Administration (FDA). Are you Eligible? (Inclusion Criteria) Must be 18 years or older - Must consent to fresh pretreatment bone marrow...

  • A Phase 1a/1b Study of LY4052031, an Antibody-Drug ConjugateTargeting Nectin-4, in Participants with Advanced or Metastatic Urothelial Carcinoma or Other Solid Tumors

    Principal Investigator:

    Alexander Z. Wei, MD

    Contact Number:

    212-342-5162

    NCT Number:

    NCT06465069

    Population:

    Adult

    Phase:

    I
    The purpose of this study is to determine whether using LY4052031 in a type of cancer that may have tumor cells that express a protein called Nectin-4 is safe and how well the cancer responds to the study drug. LY4052031 has not been approved by the US Food and Drug Administration (FDA). This is a first in human study and all of the risks are not fully known yet. Are you Eligible? (Inclusion Criteria) Must be 18 years old or older - Life expectancy must be more than 12 weeks - Must not have uncontrolled diabetes

  • An Open-Label, Multicenter Study of LY4050784, a Selective SMARCA2/BRM Inhibitor, inAdvanced Solid Tumor Malignancies with SMARCA4/BRG1 Alterations- J5M-OX-JOXA

    Principal Investigator:

    Benjamin Herzberg, MD

    Contact Number:

    212-342-5162

    NCT Number:

    NCT06561685

    Population:

    Adult

    Phase:

    I
    The purpose of this study is to test the safety of an investigational treatment called LY4050784 in subjects with solid tumors that have a particular genetic abnormality (called an alteration or mutation) of a gene called SMARCA4 and/or BRG1. LY4050784 is an investigational (or experimental) drug, taken by mouth that targets a gene called SMARCA2/BRM, and may treat certain cancers. Investigational means neither the FDA nor any other health or regulatory authority in other countries have approved LY4050784. This study will be the first time LY4050784 will be tested in humans. Are you Eligible...

  • A Phase 1a/1b Study of the pan-KRAS Inhibitor LY4066434 in Participants with KRAS Mutant SolidTumors

    Principal Investigator:

    Benjamin Herzberg, MD

    Contact Number:

    212-342-5162

    NCT Number:

    NCT06607185

    Population:

    Adult

    Phase:

    I
    This research study is being done to test the safety of an investigational treatment called LY4066434 when given alone or with other cancer drugs. LY4066434 is an investigational (or experimental) drug, taken orally. It was designed for patients that have abnormalities (also known as DNA mutations) in the KRAS gene that can occur in some types of cancer. LY4066434 is not approved by the U.S. Food and Drug Administration. Are you Eligible? (Inclusion Criteria) Must be ≥18 years of age, 2. Must be able to swallow tablets. 3. Must be able to comply with outpatient treatment, laboratory...

  • A Phase 1 Study of SGN-B6A in Advanced Solid Tumors

    Principal Investigator:

    Lanyi Nora Chen, MD

    Contact Number:

    212-342-5162

    NCT Number:

    NCT04389632

    Population:

    Adult

    Phase:

    I
    The purpose of this study is to study SGN-B6A alone, with pembrolizumab, or with pembrolizumab and one of the chemotherapy drugs (cisplatin or carboplatin). The sponsor wants to find out what its side effects are and if it works for specific types of cancer. It is not yet know if SGN-B6A alone or with other drugs is better or worse than other treatments. This clinical trial uses an experimental drug. This means the Food and Drug Administration (FDA) hasn’t approved it for sale in the United States. This drug is called SGN-B6A. This clinical trial also uses pembrolizumab. The brand name...

Pages